MX355041B - Dominios de union a albumina consenso no naturales. - Google Patents
Dominios de union a albumina consenso no naturales.Info
- Publication number
- MX355041B MX355041B MX2014014384A MX2014014384A MX355041B MX 355041 B MX355041 B MX 355041B MX 2014014384 A MX2014014384 A MX 2014014384A MX 2014014384 A MX2014014384 A MX 2014014384A MX 355041 B MX355041 B MX 355041B
- Authority
- MX
- Mexico
- Prior art keywords
- binding domains
- albumin binding
- natural consensus
- consensus albumin
- natural
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261651642P | 2012-05-25 | 2012-05-25 | |
| US201361776918P | 2013-03-12 | 2013-03-12 | |
| PCT/US2013/042429 WO2013177398A2 (en) | 2012-05-25 | 2013-05-23 | Non-natural consensus albumin binding domains |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014014384A MX2014014384A (es) | 2015-05-11 |
| MX355041B true MX355041B (es) | 2018-03-28 |
Family
ID=49622071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014014384A MX355041B (es) | 2012-05-25 | 2013-05-23 | Dominios de union a albumina consenso no naturales. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US9156887B2 (https=) |
| EP (1) | EP2855509B1 (https=) |
| JP (3) | JP2015519345A (https=) |
| KR (1) | KR102053674B1 (https=) |
| CN (1) | CN104470944B (https=) |
| AU (2) | AU2013266215B2 (https=) |
| BR (1) | BR112014029409B1 (https=) |
| CA (1) | CA2874646C (https=) |
| DK (1) | DK2855509T3 (https=) |
| EA (1) | EA036487B1 (https=) |
| ES (1) | ES2670442T3 (https=) |
| IL (2) | IL235808A (https=) |
| MX (1) | MX355041B (https=) |
| PT (1) | PT2855509T (https=) |
| WO (1) | WO2013177398A2 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9695228B2 (en) | 2012-11-21 | 2017-07-04 | Janssen Biotech, Inc. | EGFR and c-Met fibronectin type III domain binding molecules |
| CN105247118A (zh) * | 2013-03-14 | 2016-01-13 | 多伦多大学管理委员会 | 支架化肽文库以及其制备和筛选方法 |
| CA2979973A1 (en) * | 2015-04-29 | 2016-11-03 | Mediolanum Farmaceutici S.P.A. | A soluble chimeric interleukin-10 receptor and therapeutic use thereof |
| WO2016204884A1 (en) * | 2015-06-18 | 2016-12-22 | Albert Einstein College Of Medicine, Inc. | Fgf receptor ligands for treating diabetes and obesity |
| EP3374504B1 (en) * | 2015-11-09 | 2025-03-19 | CureVac SE | Optimized nucleic acid molecules |
| CN106699842B (zh) * | 2015-11-17 | 2020-06-12 | 上海交通大学 | 一种新的抗炎小分子多肽及其应用 |
| EP3423480A1 (en) | 2016-03-01 | 2019-01-09 | The Board of Trustees of the University of Illinois | L-asparaginase variants and fusion proteins with reduced l-glutaminase activity and enhanced stability |
| US10611823B2 (en) | 2016-12-14 | 2020-04-07 | Hanssen Biotech, Inc | CD137 binding fibronectin type III domains |
| NZ754187A (en) | 2016-12-14 | 2026-02-27 | Janssen Biotech Inc | Cd8a-binding fibronectin type iii domains |
| WO2018140456A1 (en) | 2017-01-24 | 2018-08-02 | Northwestern University | Active low molecular weight variants of angiotensin converting enzyme 2 (ace2) |
| EP3664832B1 (en) | 2017-08-11 | 2023-10-18 | The Board of Trustees of the University of Illinois | Truncated guinea pig l-asparaginase variants and methods of use |
| EP3765496A1 (en) | 2018-03-13 | 2021-01-20 | Affibody AB | Polypeptides based on a novel scaffold |
| KR102282240B1 (ko) * | 2018-12-06 | 2021-07-28 | 경상국립대학교산학협력단 | 지속형 엑센딘-4 및 이의 용도 |
| CN114786682B (zh) | 2019-10-14 | 2024-07-16 | Aro生物疗法公司 | 结合cd71的纤维粘连蛋白iii型结构域 |
| WO2021076574A2 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Fn3 domain-sirna conjugates and uses thereof |
| WO2021076543A1 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Epcam binding fibronectin type iii domains |
| WO2021127353A1 (en) | 2019-12-18 | 2021-06-24 | Aro Biotherapeutics Company | Serum albumin-binding fibronectin type iii domains and uses thereof |
| US12123036B2 (en) | 2020-02-26 | 2024-10-22 | Northwestern University | Soluble ACE2 variants and uses therefor |
| EP4148126A4 (en) * | 2020-03-25 | 2025-01-08 | Curigin Co.,Ltd. | ANTI-TUMOR ADENOVIRUS IMMUNO-EVASIVE |
| CA3214552A1 (en) | 2021-04-14 | 2022-10-20 | Russell C. Addis | Cd71 binding fibronectin type iii domains |
| BR112023021318A2 (pt) | 2021-04-14 | 2023-12-19 | Aro Biotherapeutics Company | Conjugados de domínio fn3-sirna e usos dos mesmos |
| CN113336860B (zh) * | 2021-06-02 | 2022-07-01 | 北京大学 | 一种具有靶向和长效功能的重组水蛭素融合蛋白及其编码基因和应用 |
| JP2025538292A (ja) * | 2022-11-09 | 2025-11-27 | レプリゲン・コーポレーション | 親和性剤 |
| EP4634216A1 (en) | 2022-12-16 | 2025-10-22 | Repertoire Immune Medicines, Inc. | T cell receptors binding hpv-16 epitopes |
| WO2025073871A1 (en) | 2023-10-03 | 2025-04-10 | Bicycletx Limited | Bicyclic peptide ligand complexes specific for tfr1 |
| WO2025125378A1 (en) * | 2023-12-12 | 2025-06-19 | Navigo Proteins Gmbh | Novel serum albumin-binding fusion proteins |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6267964B1 (en) | 1989-08-01 | 2001-07-31 | Affibody Technology Sweden Ab | Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives |
| AU672794B2 (en) * | 1992-05-07 | 1996-10-17 | Affitech As | Immunoglobulin binding proteins derived from L protein and their uses |
| WO1994012520A1 (en) | 1992-11-20 | 1994-06-09 | Enzon, Inc. | Linker for linked fusion polypeptides |
| PT1538206E (pt) | 1997-09-16 | 2010-04-12 | Centocor Ortho Biotech Inc | Método para a síntese química e construção completa de genes e genomas |
| US6670127B2 (en) | 1997-09-16 | 2003-12-30 | Egea Biosciences, Inc. | Method for assembly of a polynucleotide encoding a target polypeptide |
| US20050287153A1 (en) | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| EP2180054A1 (en) | 1999-12-24 | 2010-04-28 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
| CA2694139C (en) | 2007-07-31 | 2018-06-05 | Affibody Ab | Albumin binding polypeptide compositions |
| KR20110039220A (ko) | 2008-06-30 | 2011-04-15 | 교와 핫꼬 기린 가부시키가이샤 | 항ｃｄ27 항체 |
| BRPI0919881B1 (pt) * | 2008-10-31 | 2021-09-08 | Centocor Ortho Biotech Inc | Proteína de arcabouço e seu método de geração, biblioteca e seu método de construção, molécula de ácido nucleico, vetor de ácido nucleico, célula hospedeira, composição, dispositivo médico e artigo de fabricação |
| US8580274B2 (en) * | 2009-02-10 | 2013-11-12 | University Of The Ryukyus | Drug transporter, and adjuvant and vaccine each utilizing same |
| BRPI1008532B1 (pt) | 2009-02-12 | 2021-12-14 | Janssen Biotech, Inc | Arcabouço de proteína isolada, método para construção de uma biblioteca de arcabouço de proteína isolada, molécula de ácido nucleico isolada, vetor de ácido nucleico isolado, célula hospedeira de bactéria ou fungo, composição, dispositivo médico e artigo de manufatura para uso farmacêutico ou de diagnóstico em seres humanos |
| WO2010141329A1 (en) * | 2009-06-01 | 2010-12-09 | Medimmune, Llc | Molecules with extended half-lives and uses thereof |
| EP3165540A1 (en) | 2010-04-13 | 2017-05-10 | Celldex Therapeutics, Inc. | Antibodies that bind human cd27 and uses thereof |
| EP3569256B1 (en) | 2010-04-30 | 2022-06-15 | Janssen Biotech, Inc. | Stabilized fibronectin domain compositions, methods and uses |
| US9695228B2 (en) | 2012-11-21 | 2017-07-04 | Janssen Biotech, Inc. | EGFR and c-Met fibronectin type III domain binding molecules |
-
2013
- 2013-05-23 MX MX2014014384A patent/MX355041B/es active IP Right Grant
- 2013-05-23 US US13/901,013 patent/US9156887B2/en active Active
- 2013-05-23 BR BR112014029409-7A patent/BR112014029409B1/pt active IP Right Grant
- 2013-05-23 JP JP2015514183A patent/JP2015519345A/ja not_active Withdrawn
- 2013-05-23 DK DK13793564.9T patent/DK2855509T3/en active
- 2013-05-23 WO PCT/US2013/042429 patent/WO2013177398A2/en not_active Ceased
- 2013-05-23 KR KR1020147035989A patent/KR102053674B1/ko active Active
- 2013-05-23 EP EP13793564.9A patent/EP2855509B1/en active Active
- 2013-05-23 AU AU2013266215A patent/AU2013266215B2/en active Active
- 2013-05-23 EA EA201590136A patent/EA036487B1/ru unknown
- 2013-05-23 CN CN201380039335.8A patent/CN104470944B/zh active Active
- 2013-05-23 CA CA2874646A patent/CA2874646C/en active Active
- 2013-05-23 PT PT137935649T patent/PT2855509T/pt unknown
- 2013-05-23 ES ES13793564.9T patent/ES2670442T3/es active Active
-
2014
- 2014-11-20 IL IL235808A patent/IL235808A/en active IP Right Grant
-
2015
- 2015-09-01 US US14/842,218 patent/US20160083436A1/en not_active Abandoned
-
2017
- 2017-09-20 US US15/710,385 patent/US10280200B2/en active Active
- 2017-09-24 IL IL254652A patent/IL254652B/en active IP Right Grant
- 2017-11-17 AU AU2017261625A patent/AU2017261625B2/en active Active
-
2018
- 2018-06-18 JP JP2018115294A patent/JP7166081B2/ja active Active
-
2020
- 2020-09-23 JP JP2020158256A patent/JP2021019595A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017261625B2 (en) | Non-natural consensus albumin binding domains | |
| PH12014501736A1 (en) | Therapeutic use of p75ntr neurotrophin binding protein | |
| DK3791896T5 (da) | Kombinationsterapi med antistoffer mod claudin 18.2 til cancerbehandling | |
| TN2012000414A1 (en) | Forms of rifaximin and uses thereof | |
| MX2020010693A (es) | Uso de peptidos glp-1 de accion prolongada. | |
| MX2014011134A (es) | Compuestos de carbamato y preparacion y uso de los mismos. | |
| AU2011328009A8 (en) | Compounds and methods for treating pain | |
| PH12013501636A1 (en) | Treatment of osteoarthritis and pain | |
| NZ707086A (en) | Anti-cd40 antibodies and methods of use | |
| MX365612B (es) | Polipeptidos de factor x modificados y usos de los mismos. | |
| MX2015006973A (es) | Inmunoterapia con agentes de enlace. | |
| EP4276200A3 (en) | Fgfr-tacc fusion proteins and methods thereof | |
| PH12014502274A1 (en) | Anti-fcrn antibodies | |
| MX2015005252A (es) | Metodo novedoso para tratar infarto cardiaco utilizando fragmento de hmgb1. | |
| IL235672A0 (en) | Combined treatment involving antibodies against claudin 18.2 for the treatment of cancer | |
| PH12014502406B1 (en) | Anti-il-23p19 antibodies | |
| PL2888359T3 (pl) | Białka fuzyjne i sposoby leczenia, zapobiegania lub łagodzenia bólu | |
| MX2024008826A (es) | Composicion para la estimulacion ovarica controlada. | |
| EA201391171A1 (ru) | Формы рифаксимина и их применение | |
| MX356755B (es) | Compuestos de tipo fumagilol y metodos para su elaboración y uso. | |
| BR112014027087A2 (pt) | tablete, método para fabricação de um tablete de mesilato de bromocriptina, método para fabricação de um tablete de mesilato de bromocriptina e método de tratamento para melhorar o controle glicêmico de diabetes do tipo 2 em um paciente | |
| SG191060A1 (en) | Robo1-fc fusion protein for use in the treatment of hepatocarcinoma | |
| NZ727446A (en) | Therapeutic use of p75ntr neurotrophin binding protein | |
| PL2943215T3 (pl) | Peptydy pochodzące z laktoferycyny do zastosowania w leczeniu nowotworu | |
| SA113340398B1 (ar) | استخدام (s-(rs- سيكلوبروبيل-s-(4-{[4-{[(1r, 2r)-2- هيدروكسي-1- ميثيل بروبيل] أوكسي}-5-(تراي فلوروميثيل) بيريميدين-2- يل] أمينو} فنيل) سلفوكسيميد من أجل علاج أورام معينة |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |